Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.56 |
| ▸ | CNR2 | P34972 | 15/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.49 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15270658 | 1.00 | CNR1 (0.56) | CNR1CNR2PLA2G2AMEN1USP2 | |
| SCHEMBL31442661 | 0.90 | CNR1 (0.60) | CNR1CNR2PLA2G2AMEN1USP2 | |
| SCHEMBL31442685 | 0.90 | CNR1 (0.60) | CNR1CNR2PLA2G2AMEN1USP2 | |
| SCHEMBL16013719 | 0.88 | MGLL (0.48) | CNR1CNR2ALDH1A1 | |
| SCHEMBL16013720 | 0.88 | MGLL (0.48) | CNR1CNR2ALDH1A1 | |
| SCHEMBL5086816 | 0.85 | PLA2G2A (0.59) | CNR1CNR2PLA2G2A | |
| SCHEMBL5095901 | 0.85 | PLA2G2A (0.59) | CNR1CNR2PLA2G2A | |
| SCHEMBL31406483 | 0.85 | PLA2G2A (0.59) | CNR1CNR2PLA2G2A | |
| SCHEMBL20958133 | 0.85 | PLA2G2A (0.59) | CNR1CNR2PLA2G2A | |
| SCHEMBL31406523 | 0.85 | PLA2G2A (0.59) | CNR1CNR2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320138-B1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4320138-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | Bachem Holding AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022214692-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | POLR2H, POLR2E, SUB1 | CNR1 1181/4885CNR2 1613/4885PLA2G2A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.